While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate [Yahoo! Finance]
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Tarsus Pharmaceuticals (NASDAQ:TARS) was given a new $100.00 price target on by analysts at Barclays PLC.
Can Tarsus Pharmaceuticals Stock Still Offer Value After Its 48% 2025 Rally? [Yahoo! Finance]
Tarsus to Participate in Upcoming Investor Conference